Cargando…

Editorial: can China master the guideline challenge?

China is experiencing increased health care use and expenditures, without sufficient controls to ensure quality and value. Transparent, cost-conscious and patient-centered guidelines based on the best available evidence could help establishing these quality and practice measures. We examined how gui...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Kehu, Chen, Yaolong, Li, Youping, Schünemann, Holger J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544593/
https://www.ncbi.nlm.nih.gov/pubmed/23302417
http://dx.doi.org/10.1186/1478-4505-11-1
_version_ 1782255802805911552
author Yang, Kehu
Chen, Yaolong
Li, Youping
Schünemann, Holger J
author_facet Yang, Kehu
Chen, Yaolong
Li, Youping
Schünemann, Holger J
author_sort Yang, Kehu
collection PubMed
description China is experiencing increased health care use and expenditures, without sufficient controls to ensure quality and value. Transparent, cost-conscious and patient-centered guidelines based on the best available evidence could help establishing these quality and practice measures. We examined how guidelines could support the Chinese health reform. Specifically, we summarized the current state of the art and related challenges in guideline development and explored possible solutions in the context of the Chinese health reform. China currently lacks capacity for evidence-based guideline development and coordination by a central agency. Most Chinese guideline users rely on recommendations developed by professional groups that lack demonstration of transparency (including conflict of interest management and evidence synthesis) and quality. These deficiencies appear larger than in other regions of the world. In addition, misperceptions about the role of guidelines in assisting practitioners as opposed to providing rules requiring adherence, and a perception that traditional Chinese medicine (TCM) cannot be appropriately incorporated in guidelines are present. China’s capacity could be strengthened by a central guideline agency to provide or coordinate evidence synthesis for guideline development and to oversee the work of guideline developers. China can build on what is known and work with the international community to develop methods to meet the challenges of evidence-based guideline development.
format Online
Article
Text
id pubmed-3544593
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35445932013-01-16 Editorial: can China master the guideline challenge? Yang, Kehu Chen, Yaolong Li, Youping Schünemann, Holger J Health Res Policy Syst Commentary China is experiencing increased health care use and expenditures, without sufficient controls to ensure quality and value. Transparent, cost-conscious and patient-centered guidelines based on the best available evidence could help establishing these quality and practice measures. We examined how guidelines could support the Chinese health reform. Specifically, we summarized the current state of the art and related challenges in guideline development and explored possible solutions in the context of the Chinese health reform. China currently lacks capacity for evidence-based guideline development and coordination by a central agency. Most Chinese guideline users rely on recommendations developed by professional groups that lack demonstration of transparency (including conflict of interest management and evidence synthesis) and quality. These deficiencies appear larger than in other regions of the world. In addition, misperceptions about the role of guidelines in assisting practitioners as opposed to providing rules requiring adherence, and a perception that traditional Chinese medicine (TCM) cannot be appropriately incorporated in guidelines are present. China’s capacity could be strengthened by a central guideline agency to provide or coordinate evidence synthesis for guideline development and to oversee the work of guideline developers. China can build on what is known and work with the international community to develop methods to meet the challenges of evidence-based guideline development. BioMed Central 2013-01-09 /pmc/articles/PMC3544593/ /pubmed/23302417 http://dx.doi.org/10.1186/1478-4505-11-1 Text en Copyright ©2013 Yang et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Yang, Kehu
Chen, Yaolong
Li, Youping
Schünemann, Holger J
Editorial: can China master the guideline challenge?
title Editorial: can China master the guideline challenge?
title_full Editorial: can China master the guideline challenge?
title_fullStr Editorial: can China master the guideline challenge?
title_full_unstemmed Editorial: can China master the guideline challenge?
title_short Editorial: can China master the guideline challenge?
title_sort editorial: can china master the guideline challenge?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544593/
https://www.ncbi.nlm.nih.gov/pubmed/23302417
http://dx.doi.org/10.1186/1478-4505-11-1
work_keys_str_mv AT yangkehu editorialcanchinamastertheguidelinechallenge
AT chenyaolong editorialcanchinamastertheguidelinechallenge
AT liyouping editorialcanchinamastertheguidelinechallenge
AT schunemannholgerj editorialcanchinamastertheguidelinechallenge